Small Cell Lung Cancer (SCLC)

Latest News

Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.

Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC

April 16th 2025

Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.

Tarlatamab Displays Overall Survival Benefit in Relapsed SCLC

By Roman Fabbricatore

April 14th 2025

Real-world data may support a new way to consider follow-up treatment for patients who are elderly with extensive-stage small cell lung cancer.

Chemoimmunotherapy Elicits Survival Benefit in Older ES-SCLC Population

By Russ Conroy

April 10th 2025

$Investigators will assess the safety, pharmacology, and maximum tolerated dose of ST-001 in relapsed/refractory SCLC as part of a phase 1a/1b trial.$

FDA Accepts IND Application for ST-001 in Relapsed/Refractory SCLC

By Russ Conroy

April 9th 2025

CHMP Grants Positive Opinion to Tislelizumab/Chemotherapy in Frontline ES-SCLC

By Tim Cortese

April 1st 2025

Latest CME Events & Activities

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

26th Annual International Lung Cancer Congress®

July 25-26, 2025

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies